These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37438870)

  • 21. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
    Hendset M; Hermann M; Lunde H; Refsum H; Molden E
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG; Preskorn S; Hochfeld M; Meng X
    J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
    Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
    Molden E; Waade RB; Hoff M; Haslemo T
    Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
    Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
    Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
    Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
    Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
    Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
    Waade RB; Hermann M; Moe HL; Molden E
    Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN).
    Atanasova SY; von Ahsen N; Toncheva DI; Dimitrov TG; Oellerich M; Armstrong VW
    Clin Biochem; 2005 Mar; 38(3):223-8. PubMed ID: 15708542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
    Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
    Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
    Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
    J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus.
    Lee JY; Vinayagamoorthy N; Han K; Kwok SK; Ju JH; Park KS; Jung SH; Park SW; Chung YJ; Park SH
    Arthritis Rheumatol; 2016 Jan; 68(1):184-90. PubMed ID: 26316040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
    Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
    J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.